Bridging the Gap: EU vs. US Clinical Evidence Requirements

For medical device manufacturers, the path to market access requires navigating two distinct clinical evidence frameworks: the EU MDR/IVDR and the US FDA. Misunderstanding the nuances between these regions is a leading cause of regulatory delays and significant rework.

The EU Framework: Performance and GSPR Alignment

In Europe, under MDR (2017/745) and IVDR (2017/746), clinical evidence is built around demonstrating that a device meets its General Safety and Performance Requirements (GSPR).

• Clinical Evaluation Report (CER): A mandatory document that links clinical data directly to the device's intended use and specific claims.
• Continuous Oversight: Evidence is not static; it requires Post-Market Clinical Follow-up (PMCF) with clearly defined objectives and timelines.
• Rigorous Review: Notified Bodies scrutinize equivalence justifications and the systematic nature of literature reviews.

The US Framework: Risk-Driven Safety and Effectiveness

The FDA approach is categorized by the device's risk profile rather than a fixed evaluation template:

• PMA (Premarket Approval): Required for high-risk devices, demanding prospective clinical studies to prove safety and effectiveness.
• 510(k): Relies on proving substantial equivalence to a legally marketed predicate device.
• De Novo: Used for novel devices with low-to-moderate risk that do not have a predicate.

ISO 14155: The Common Language of Clinical Credibility

Sitting between these two frameworks is ISO 14155:2020, the standard for Good Clinical Practice (GCP) for medical device investigations.

A study conducted under ISO 14155 ensures data integrity and subject protection. Because it integrates risk management principles from ISO 14971, data generated under this standard is generally acceptable to both the FDA and EU authorities. Treating this standard as a core strategy rather than an afterthought is essential for global alignment.

Common Weaknesses in Clinical Strategy

Many sponsors fall into predictable traps that hinder market access:

• Misaligned Endpoints: Clinical trial endpoints that do not support the marketing claims on the label.
• Weak Equivalence: Equivalence arguments that lack technical or biological depth and collapse during review.
• Non-Systematic Reviews: Literature searches that are not reproducible or transparent.
• Stagnant PMCF: Plans that are written once for the initial submission but never updated with real-world data.

Conclusion

Bridging these clinical frameworks early in development is not just a bureaucratic task; it is strategic risk management. When your clinical evidence, risk documentation, and labeling tell a consistent story, market access becomes faster and more defensible.